Shanghai API maker slapped around in FDA warning letter

FDA building

The FDA has slammed a Shanghai API maker in a warning letter for what it called “systemic data manipulation” which raised questions about the quality of the Chinese company’s products.

FDA inspectors were in the Tai Heng Industry plant in May 2015, according to the warning letter, which the FDA issued earlier this month and posted this week.

Inspectors said that batch samples were routinely retested following failing or atypical results until acceptable results were obtained, and the failures were never investigated to determine their cause. When the retesting was done, quality-control analysts would then use administrator privileges and passwords from unprotected equipment to manipulate results on the high performance liquid chromatography (HPLC) computer. 

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

On top of that, operators used “mock” sheets to capture critical manufacturing data, then backdated batch production records days after operations ended, the warning letter said.

The FDA was not satisfied with the company’s pledge to have a third-party company audit its quality systems. It said it also wanted a complete investigation into the data manipulation and reports on potential effects on products. And it wants Tai Heng to figure out why it was getting out-of-spec results and then fix the problems, not cover them up.  

The letter to Tai Heng was one of two the FDA posted this week. The agency also found a list of faults at a Baesweiler, Germany, API plant operated by BBT Biotech. It said the company has shipped APIs to the U.S. since 2012 without ever doing stability testing to support the expiration dates it put on its products and was not adequately investigating out-of-spec issues.  

- read the warning letter

Related Articles:
FDA issues warning letter to Germany's BBT Biotech
EMA pulls GMP certificate for U.S. facility
FDA lambasts Sri Krishna Pharma plant in new warning letter
EMA bans APIs from two Indian manufacturers

Suggested Articles

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.